logo
Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update

Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update

Yahoo13-05-2025

TWYMEEG® consolidated gross sales in Japan for Sumitomo Pharma Fiscal Year 20241 achieved JPY 7.6 billion (EUR 47,2 million)2, in line with Sumitomo Pharma's latest guidance3
Sumitomo Pharma forecast for TWYMEEG®'s FY 20254 of JPY 11.2 billion (EUR 69,4 million2), representing a 47% increase over FY 2024 sales
In FY2024, Poxel started receiving 10% royalties on TWYMEEG® net sales, and from FY2025 5 anticipates receiving escalating double-digit royalties and additional sales-based payments upon achievement of contractual sales thresholds
Regulatory approval on April 8, 2025, by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan enabling Sumitomo Pharma to immediately start promoting the use of TWYMEEG® (Imeglimin) in type 2 diabetic patients with moderate to severe renal impairment
Ongoing discussions with 1/ creditors to ensure continuity of the Company's operations and 2/ potential partners for the development of pipeline products
LYON, France, May 13, 2025--(BUSINESS WIRE)--Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today reported its revenue for the quarter ended March 31, 2025 and provided corporate update.
Thomas Kuhn, Chief Executive Officer of Poxel, stated: "TWYMEEG® has further demonstrated its strong potential in FY 20241 with the commercial performance in Japan representing a 65% increase over FY 2023. This robust growth is expected to continue in FY 2025 and beyond, and should be further strengthened driven by a number of key recent milestones, including the recent regulatory approval in Japan allowing TWYMEEG® to be prescribed to type 2 diabetic patients with moderate to severe renal impairment, a key patient population, particularly elderly individuals with renal impairment, who are faced with limited treatment options. In parallel of these achievements, our top priority remains to secure a path forward for the Company. We continue to be actively engaged in discussions with our creditors with the aim of reaching a structuring solution that would ensure the continuity of the Company's operations, and with potential partners to develop strategic opportunities to unlock the value of our pipeline of products."
Commercial and Clinical Update
TWYMEEG® (Imeglimin)
For the quarter ended March 2025, TWYMEEG® gross sales in Japan totalled JPY 1.9 billion (EUR 12 million)2. As a result, for Sumitomo Pharma's FY 20241, TWYMEEG® gross sales reached JPY 7.6 billion (EUR 47.1 million)2, in line with Sumitomo Pharma's most recent FY 2024 guidance (JPY 7.9 billion) and representing an increase by 65% over FY 2023.
For its FY 20255, Sumitomo Pharma forecasts gross sales for TWYMEEG® of JPY 11.2 billion4 (EUR 69.4 million)2 which would represent a 47% increase over FY 2024 TWYMEEG® gross sales. This forecast includes an incremental uptake among type 2 diabetic patients with renal impairment following the recent approval by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to revise TWYMEEG® package insert for patients with renal impairment with eGFR (estimated glomerular filtration rate) less than 45 mL/min/1.73m2.
Based on this FY 2025 forecast, TWYMEEG® could reach JPY 10 billion net sales (EUR 62 million)2 entitling Poxel to receive 12% royalties on all TWYMEEG® net sales and a second sales-based payment of JPY 1 billion (EUR 6.3 million)2. Following the recent royalty monetization agreement with OrbiMed, these proceeds will go exclusively towards the reimbursement of the bonds issuance. Beyond 2025, Poxel expects to receive escalating double-digit royalties as well as additional sales-based payments upon achievement of contractually based sales thresholds.
In August 2024, topline results from the post-marketing clinical study, TWINKLE (TWYMEEG® in diabetic patients with renal impairment: A post-marketing long-term study) conducted by Sumitomo Pharma in Japanese type 2 diabetic patients with renal impairment confirmed TWYMEEG®'s safety and tolerability profile, which is consistent with prior clinical studies. Based on these results, Sumitomo Pharma led discussions with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan leading to the revision of TWYMEEG® package insert for patients with renal impairment with eGFR (estimated glomerular filtration rate) less than 45 mL/min/1.73m2 on April 8, 2025. This approval has enabled Sumitomo Pharma to immediately start promoting the use of TWYMEEG® in this population.
This regulatory milestone builds on the recently granted patent (n°7635474) by the Japanese Patent Office to Poxel6 covering the use of Imeglimin in type 2 diabetic patients with moderate to severe renal impairment until 2039, strengthening TWYMEEG®'s patent portfolio in Japan and protecting its use in this population. Poxel previously received the grant of this patent in China7, the world's second largest type 2 diabetes market, further supporting ongoing discussions initiated by the Company to develop Imeglimin beyond Japan.
PXL065
On March 20, 2025, positive top-line results for PXL065 were obtained from a preclinical study conducted in a mouse model of hypertrophic cardiomyopathy (HCM), the most common genetic cardiac disorder. The preclinical study was financed through a grant by DZHK8 and conducted at the TUM University Hospital German Heart Center under a research collaboration. After 10 weeks of treatment, a significant reduction in myocardial hypertrophy associated with a significant reduction in cardiac fibrosis was demonstrated, highlighting the potential of PXL065 in this pathology. These results further support the clinical development of PXL065 as a potential disease-modifying treatment for symptomatic and asymptomatic HCM and will be presented at a future scientific meeting.
First Quarter 2025 Consolidated Revenue
Poxel reported EUR 1,066 thousand2 consolidated revenue for the quarter ended March 31, 2025, representing a 137% increase compared to the 2024 Q1 revenue.
Consolidated revenue for the first quarter of 2025 reflects JPY 172 million (EUR 1,066 thousand2) of royalty revenue from Sumitomo Pharma, which represents 10% of TWYMEEG® net sales in Japan. Based on the current forecast, Poxel expects to receive at least 12% royalties on TWYMEEG® net sales in Japan through the Sumitomo Pharma fiscal year 20255. As part of the Merck Serono licensing agreement, Poxel will pay Merck Serono a fixed 8% royalty based on the net sales of Imeglimin, independent of the level of sales. According to the Royalty Monetization agreement with OrbiMed, the positive net Royalties will be fully dedicated to the repayment of the bonds.
EUR (in thousands)
Q1 2025*
Q1 2024
3 months
3 months
Sumitomo Pharma Agreement
1,066
449
Other
-
-
Total consolidated revenues
1,066
449
*Unaudited data
Update on existing event of default under the IRIS and IPF Partners existing bond financing agreements and search of structuring financial solution to ensure the continuity of the Company
Since the announcement by the Company of the events of default under the IRIS and IPF Partners outstanding bond financing agreements triggered by the non-adoption of the financial delegations at the Combined General Meeting held on February 11, 2025, the Board of Directors and the Management of Poxel continue to actively negotiate with the Company's creditors, with the aim of reaching a structuring solution that would ensure the continuity of the Company's operations. As announced on April 16, 2025, Poxel's financial outlook remains highly constrained with a cash runway currently estimated through June 2025, depending on the outcome of current discussions with the Company's creditors.
In parallel, the Company is also progressing discussions with several potential partners for the development of its pipeline products.
As already announced on April 16, 2025, given the potential impact on the Company's financial statements of the negotiations with the Company's creditors and potential partners, Poxel has postponed the approval and publication of its 2024 Full-Year Results. A new date will be communicated once these negotiations are finalized.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.
Glossary
You will find below a list of words and/or expressions that are used in this press release or in Poxel's communication, with the aim of bringing clarification and transparency:
Sumitomo Pharma fiscal year runs April to March. As an example, Fiscal Year 2024 is April 1, 2024, through March 31, 2025.
TWYMEEG® royalties: As per the Sumitomo Pharma's agreement, Poxel is entitled to receive royalties from the sales of TWYMEEG® (Imeglimin) in Japan
Sumitomo Pharma communicates gross sales of TWYMEEG®, while TWYMEEG® royalties are calculated on net sales.
Net sales represent the amount of gross sales to which are deducted potential rebates, allowances, and costs such as prepaid freight, postage, shipping, customs duties and insurance charges.
Poxel is entitled to receive escalating royalties of 8-18% on TWYMEEG® net sales from Sumitomo Pharma.
Positive net royalties: as part of the Merck Serono licensing agreement, Poxel will pay Merck Serono a fixed 8% royalty based on the net sales of TWYMEEG®, independent of the level of sales. All royalties that Poxel receives from TWYMEEG® net sales above that 8% level are considered as positive net royalties. Net royalties will therefore be positive for Poxel when TWYMEEG® net sales exceed JPY 5 billion in a fiscal year and royalties reach 10% and above.
Poxel refers to the Group Poxel, including its affiliates (Poxel Inc. and Poxel KK) as well as the 3 security trusts set up as part of the Royalty monetization and debt restructuring operations announced on September 30, 2024.
_______________________________
1 Sumitomo Pharma fiscal year 2024 ends March 31, 2025
2 Converted at the exchange rate on March 31, 2025
3 As per Sumitomo Pharma FY2024 forecast of JPY 7.9 billion published on January 31, 2025
4 As per Sumitomo Pharma FY2024 forecast published on May 13, 2025
5 Sumitomo Pharma fiscal year 2025 ends March 31, 2026
6 "Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment", on March 31, 2025
7 "Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment", on January 20, 2025
8 DZHK: German Center for Cardiovascular Research (Deutsches Zentrum für Herz-Kreislauf-Forschung)
View source version on businesswire.com: https://www.businesswire.com/news/home/20250512270586/en/
Contacts
Investor relations / Media NewCapAurélie Manavarere, Théo Martin / Arthur Rouilléinvestors@poxelpharma.com +33 1 44 71 94 94

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Moxie and Revision Skincare® Announce Strategic Partnership to Empower High-Growth Medspas
Moxie and Revision Skincare® Announce Strategic Partnership to Empower High-Growth Medspas

Yahoo

time25 minutes ago

  • Yahoo

Moxie and Revision Skincare® Announce Strategic Partnership to Empower High-Growth Medspas

Streamlined Ordering and Exclusive Education Now Available to Moxie-Supported Practices BROOKLYN, N.Y., June 11, 2025 /PRNewswire/ -- Moxie, the growth engine supporting over 400 aesthetic practices nationwide, today announced a strategic partnership with Revision Skincare®, the gold standard in science-backed, clinically proven skincare. This partnership brings Moxie-supported practices direct access to Revision's line of medical grade skincare, streamlined ordering, and elevated educational resources—all designed to drive profitability, operational efficiency, and exceptional client outcomes. "Independent medspas are the heartbeat of our specialty," said Kamau Massey, CEO of Moxie. "By partnering with Revision Skincare, we're expanding the ways in which we give our practices access to elite-tier products and business tools. It's about helping them compete—and win—at the highest level." This collaboration reflects a shared vision: empowering aesthetic entrepreneurs with the kind of brand alignment, service experience, and margin-boosting resources typically reserved for major enterprise clinics. "Our mission has always been to support skincare professionals with advanced innovation and education," said Joe Blahnik, Chief Sales Officer Revision Skincare®. "Moxie's commitment to the success of aesthetic practices mirrors our own—and together, we're making it easier than ever for providers to deliver exceptional results." This partnership is part of Moxie's ongoing commitment to building a best-in-class ecosystem for medspa success—uniting trusted brands that help independent practices grow, differentiate, and deliver exceptional patient experiences. About Moxie Moxie is the aesthetic practice growth and operating engine, helping medspa entrepreneurs reach multimillion dollar growth—with marketing, compliance, coaching, software, and VIP pricing, all in one place. From launch to scale, Moxie powers ambitious injectors and aesthetic entrepreneurs with the infrastructure, strategy, and partnerships they need to win in a competitive industry. About Revision Skincare® Revision Skincare® delivers high-performing, clinically validated skincare formulations rooted in rigorous research and testing. Trusted by professionals in over thirty countries across the globe, their award-winning products are designed to deliver real results—without compromising long-term skin health. Brandi EppolitoHead of MarketingMoxiebrandi@ This release was issued through WebWire®. For more information, visit View original content: SOURCE Moxie Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Natural Grocers® Celebrates National Arkansas Day with a Special Gift and Savings, June 15-17, 2025
Natural Grocers® Celebrates National Arkansas Day with a Special Gift and Savings, June 15-17, 2025

Yahoo

timean hour ago

  • Yahoo

Natural Grocers® Celebrates National Arkansas Day with a Special Gift and Savings, June 15-17, 2025

Family-Operated grocer offers Arkansas {N}power® members a free state-themed Natural Grocers reusable bag and additional in-store savings LAKEWOOD, Colo., June 11, 2025 /PRNewswire/ -- Natural Grocers®, the leading family-operated organic and natural grocery retailer in the U.S., invites customers to its second annual "Celebrate Arkansas" event, June 15-17, at its three Arkansas locations. In honor of National Arkansas Day, {N}power® members will receive a free, limited-edition, state-themed Natural Grocers reusable bag, and a $5-off coupon toward in-store purchases. NATURAL GROCERS: PROUDLY SERVING THE NATURAL STATEHeadquartered in Colorado, Natural Grocers opened its first store in "The Natural State" in Fayetteville in 2015. Today, the company proudly serves Arkansans at three locations: Fayetteville Jonesboro Little Rock "Natural Grocers started back in 1955 from very humble beginnings. As we expanded beyond our Colorado roots, we were embraced by health-conscious communities seeking high-quality natural and organic products at our Always AffordableSM prices," said Raquel Isely, vice president of marketing for Natural Grocers. "Since opening our first Arkansas store in 2015, we've felt right at home. We're proud to serve Arkansans with products that meet our high standards, which reflect our commitment to the health of humans, the welfare of animals and the principles of regenerative agriculture. That commitment, along with our knowledgeable crew and welcoming atmosphere, is what keeps customers coming back to our stores in Fayetteville, Jonesboro and Little Rock." ARKANSAS {N}POWER® MEMBERS SAVE & CELEBRATE Natural Grocers will be celebrating National Arkansas Day by honoring its customers with a freebie and extra savings for {N}power members from June 15-17, 2025. June 15-17: All {N}power members at all Arkansas stores will receive a FREE, limited-edition, reusable shopping bag featuring each of the 21 states Natural Grocers has a presence in—including Arkansas, while supplies last.[i] June 15-17: {N}power members will enjoy extra savings with a $5 off coupon.[ii] SIGN UP & SAVENot an {N}power member? Not a problem! Discover {N}power, Natural Grocers' free customer rewards program, and enjoy exclusive discounts, deals, and surprise offers. You'll earn valuable rewards points with every visit. Customers can sign up for {N}power here.[iii] Customers can also download the Natural Grocers App for easy access to {N}power benefits and more. A COMMITMENT TO ARKANSAS CREW:Natural Grocers provides careers for over 50 Crew members in the state of Arkansas. The company is passionate about ensuring that its employees can live a healthy, balanced life. Natural Grocers is committed to positively impacting Crew's physical, emotional and financial well-being with free nutrition education programs, excellent benefits and access to the highest quality, affordably priced products. Click here to learn more about career options with Natural Grocers (search by store and state – including Arkansas). LEARN MORE Subscribe to the Free Health Hotline® Magazine to learn more about a natural approach to living with monthly sale items, recipes and educational articles. To keep up with the latest that Natural Grocers has to offer, follow them on Facebook, Instagram, TikTok or YouTube. For media inquiries or sample requests, please email kmacarelli@ ABOUT NATURAL GROCERS BY VITAMIN COTTAGEFounded in 1955, Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) is an expanding specialty retailer of natural and organic groceries, body care products, and dietary supplements. The grocery products sold by Natural Grocers must meet strict quality guidelines and may not contain artificial flavors, preservatives, or sweeteners (as defined by its standards), synthetic colors, or partially hydrogenated or hydrogenated oils. The Company sells only USDA-certified organic produce and exclusively pasture-raised, non-confinement dairy products, and free-range eggs. Natural Grocers' flexible smaller-store format allows it to offer affordable prices in a shopper-friendly, clean, and convenient retail environment. The Company also provides extensive free science-based Nutrition Education programs to help customers and Crew make informed health and nutrition choices. Natural Grocers is committed to its 5 Founding Principles—including its "Commitment to Community" and "Commitment to Crew". In fiscal year 2024, the Company invested more than $15 million in incremental compensation and discretionary payments for Crew. Headquartered in the Union Square neighborhood of Lakewood, CO, Natural Grocers has 169 stores in 21 states. Visit for more information and store locations. [i] Offer available only to {N}power members. Limit one bag per customer. Only valid 6/15/25 to 6/17/25 at participating Arkansas stores, while supplies last. Quantity limited to stock on hand; no rain checks. [ii] Offer available only to registered {N}power members, for in store purchases at participating Arkansas Natural Grocers stores, 6/15/25 to 6/17/25. Customer must load the reward via {N}power email or app prompt before shopping. $5 discount will be applied to product's regular non-discounted price. A minimum purchase of $25 is required to use the $5 off coupon. Must present phone number at checkout to accumulate towards the $25 requirement in one transaction. [iii] Sign up by 6/15/25 to receive this coupon via email or app. {N}power® offers are available only to registered members and are subject to program terms and conditions available at and privacy available at Natural Grocers reserves the right to correct errors. Void where prohibited by law. Natural Grocers employees, including members of their household, are not eligible. View original content to download multimedia: SOURCE Natural Grocers by Vitamin Cottage, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Julius Baer Successfully Places EUR 500 Million Senior Unsecured Notes
Julius Baer Successfully Places EUR 500 Million Senior Unsecured Notes

Yahoo

timean hour ago

  • Yahoo

Julius Baer Successfully Places EUR 500 Million Senior Unsecured Notes

ZURICH - June 11, 2025 (NEWMEDIAWIRE) - Today, Julius Baer Group Ltd. successfully placed EUR 500 million 5-year senior unsecured notes through ELM B.V., a repackaging issuance entity incorporated in the Netherlands. This EUR senior unsecured issuance allows Julius Baer to further diversify its funding strategy in international debt markets. The transaction was targeted at European institutional investors and the proceeds will be used for general corporate purposes. Julius Baer Group Ltd. will issue loan notes to, and which are held by, ELM B.V. (or a nominee acting on its behalf), which in turn will issue its own notes to investors secured by the Julius Baer Group Ltd. loan notes. The securities carry a fixed-rate, annually payable coupon set at 3.375% per annum and have been issued in denominations of EUR 100,000. An application for admission to trading of the notes issued by ELM B.V. on Euronext Dublin will be made. ContactsMedia Relations, tel. +41 (0) 58 888 8888Investor Relations, tel. +41 (0) 58 888 5256 This announcement is not and shall not be interpreted or construed as a solicitation to purchase any securities of/in Julius Baer Group. About Julius Baer Julius Baer is the leading Swiss wealth management group and a premium brand in this global sector, with a focus on servicing and advising sophisticated private clients. In all we do, we are inspired by our purpose: creating value beyond wealth. At the end of April 2025, assets under management amounted to CHF 467 billion. Bank Julius Baer & Co. Ltd., the renowned Swiss private bank with origins dating back to 1890, is the principal operating company of Julius Baer Group Ltd., whose shares are listed on the SIX Swiss Exchange (ticker symbol: BAER) and are included in the Swiss Leader Index (SLI), comprising the 30 largest and most liquid Swiss stocks. Julius Baer is present in around 25 countries and 60 locations. Headquartered in Zurich, we have offices in key locations including Bangkok, Dubai, Dublin, Frankfurt, Geneva, Hong Kong, London, Luxembourg, Madrid, Mexico City, Milan, Monaco, Mumbai, Santiago de Chile, Shanghai, Singapore, Tel Aviv, and Tokyo. Our client-centric approach, our objective advice based on the Julius Baer open product platform, our solid financial base, and our entrepreneurial management culture make us the international reference in wealth management. For more information visit our website at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store